title: NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
abstract: There is an urgent need to transform basic research discoveries into tools for treatment and prevention of mental illnesses. This article presents an overview of the National Institute of Mental Health (NIMH) programs and resources to address the challenges and opportunities in psychiatric drug development starting at the point of discovery through the early phases of translational research. We summarize NIMH and selected National Institutes of Health (NIH) efforts to stimulate translation of basic and clinical neuroscience findings into novel targets, models, compounds, and strategies for the development of innovative therapeutics for psychiatric disorders. Examples of collaborations and partnerships among NIMH/NIH, academia, and industry are highlighted.
authors.affiliation: Divison of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, Bethesda, MD 20892, USA. lbrady@mail.nih.gov
authors.forename: Linda S
authors.initials: LS
authors.lastname: Brady
authors.forename: Lois
authors.initials: L
authors.lastname: Winsky
authors.forename: Wayne
authors.initials: W
authors.lastname: Goodman
authors.forename: Mary Ellen
authors.initials: ME
authors.lastname: Oliveri
authors.forename: Ellen
authors.initials: E
authors.lastname: Stover
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods; D004341:Drug Evaluation / Q000592:standards; D004345:Drug Industry; D006078:Government Programs; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009315:National Institute of Mental Health (U.S.); D009316:National Institutes of Health (U.S.); D055818:Public-Private Sector Partnerships; D012109:Research Support as Topic; D014481:United States; D014495:Universities
references.citation: Am J Psychiatry. 2008 Feb;165(2):214-20
references.pmid: 18172018
references.citation: Schizophr Res. 2004 Dec 15;72(1):5-9
references.pmid: 15531402
references.citation: Schizophr Bull. 2007 Sep;33(5):1131-7
references.pmid: 17630405
references.citation: Nature. 2007 Aug 9;448(7154):645-6
references.pmid: 17687303
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2047
references.pmid: 18626470
references.citation: Bioorg Med Chem Lett. 2007 Nov 1;17(21):5783-9
references.pmid: 17827006
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2061-79
references.pmid: 18046305
references.citation: Neuropsychopharmacology. 2009 Jan;34(1):204-12
references.pmid: 18830238
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2048-60
references.pmid: 18216778
references.citation: Mol Cell Neurosci. 2008 Feb;37(2):187-95
references.pmid: 18055216
references.citation: Schizophr Bull. 2005 Jan;31(1):5-19
references.pmid: 15888422
references.citation: Biol Psychiatry. 2007 Dec 1;62(11):1324-33
references.pmid: 17678633
references.citation: Biol Psychiatry. 2007 Dec 15;62(12):1337-9
references.pmid: 18054535
references.citation: Neuropsychopharmacology. 2007 Nov;32(11):2360-8
references.pmid: 17342171
references.citation: J Biomol Screen. 2008 Feb;13(2):120-7
references.pmid: 18216391
references.citation: Nat Rev Drug Discov. 2007 Jul;6(7):521-32
references.pmid: 17599084
references.citation: Nat Rev Drug Discov. 2007 Mar;6(3):189-201
references.pmid: 17330070
references.citation: Science. 2004 Nov 12;306(5699):1138-9
references.pmid: 15542455
references.citation: Nat Rev Drug Discov. 2008 Feb;7(2):107-9
references.pmid: 18246607
references.citation: Bioorg Med Chem Lett. 2008 Feb 1;18(3):885-90
references.pmid: 18178088
references.citation: Am J Psychiatry. 2008 Feb;165(2):203-13
references.pmid: 18172019
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2080-92
references.pmid: 18172433
references.citation: J Physiol. 2008 Mar 15;586(6):1503-8
references.pmid: 18202092
references.citation: Schizophr Bull. 2006 Apr;32(2):214-9
references.pmid: 16481659
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8
references.pmid: 17360345
references.citation: Trends Pharmacol Sci. 2007 Aug;28(8):390-6
references.pmid: 17629962
references.citation: JAMA. 2003 Mar 12;289(10):1278-87
references.pmid: 12633190
references.citation: Bioorg Med Chem Lett. 2008 Feb 15;18(4):1297-303
references.pmid: 18243697
references.citation: Nat Biotechnol. 2007 Mar;25(3):266
references.pmid: 17344867
references.citation: Annu Rep Med Chem. 2007;42:401-416
references.pmid: 32287469
references.citation: Schizophr Bull. 2007 Sep;33(5):1100-19
references.pmid: 17617664
references.citation: Mol Pharmacol. 2008 Apr;73(4):1213-24
references.pmid: 18171729
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
references.pmid: 16803859
references.citation: Psychopharmacology (Berl). 2007 Mar;191(1):5-13
references.pmid: 16718480
references.citation: Mol Psychiatry. 2006 Jan;11(1):11-7
references.pmid: 16355250
references.citation: Mol Pharmacol. 2007 Jul;72(1):1-7
references.pmid: 17405872
references.citation: Schizophr Bull. 2007 May;33(3):805-22
references.pmid: 16931542
references.citation: Schizophr Bull. 2007 Sep;33(5):1093-9
references.pmid: 17673495